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The aims of this study were to compare a novel PCR-based Chlamydia trachomatis detection and genotyping
(Ct-DT) assay with the FDA-approved, commercially available C. trachomatis detection Hybrid Capture 2
(HC2) assay and to investigate the C. trachomatis serovar distribution among young women in a rural Costa
Rican study population. A total of 5,828 sexually active women participating in a community-based trial in
Costa Rica were tested for C. trachomatis by HC2. A sample of 1,229 specimens consisting of 100% HC2 C.
trachomatis-positive specimens (n  827) and a random sample of 8% HC2 C. trachomatis-negative specimens
(n  402) were tested with the Ct-DT assay. Agreement between the two assays was determined by the
unweighted kappa statistic. Discrepant specimens were tested with a second commercially available test
(COBAS TaqMan). The Ct-DT-positive specimens were further analyzed with the Ct-DT genotyping step to
investigate the distribution of 14 different C. trachomatis serovars (A, B/Ba, C, D/Da, E, F, G/Ga, H, I/Ia, J, K,
L1, L2/L2a, and L3). After accounting for the sampling fraction selected for Ct-DT testing, crude agreement
with the HC2 assay was 98% and the kappa was 0.92 (95% confidence interval [CI], 0.89 to 0.97). The 33
discordant samples that were further analyzed with the COBAS TaqMan test showed better agreement with the
Ct-DT assay (31/33, P < 0.001). Among the 806 Ct-DT-positive samples, serovar E was the most common
serovar (31%), followed by serovars F and D (both 21%) and serovar I (15%). In conclusion, the novel Ct-DT
assay permits reliable detection and identification of C. trachomatis serovars.
Chlamydia trachomatis is the most prevalent sexually trans-
mitted bacterial pathogen. Annually, an estimated 90 million
new cases occur worldwide (32). Up to 50 and 75% of the
urogenital C. trachomatis infections in men and women, re-
spectively, remain asymptomatic. Infections can persist for
months and, if untreated, can lead to severe reproductive prob-
lems such as pelvic inflammatory disease in women (10, 23, 31)
and epididymitis in men (2). Furthermore, C. trachomatis infec-
tion facilitates the transmission of human immunodeficiency virus
(6), and some studies have also suggested a potential role for C.
trachomatis as a cofactor in cervical cancer among human papil-
lomavirus (HPV)-positive women (18, 26, 27).
Strains of C. trachomatis have traditionally been classified
into serovars based on reactivity with specific monoclonal an-
tibodies after culture of the strain (14, 21, 30). In contrast, the
current routine laboratory diagnosis of C. trachomatis infection
often involves molecular methods such as PCR or nucleic acid
hybridization assays. In general, these assays aim at detection
of the cryptic plasmid (COBAS TaqMan and COBAS Ampli-
cor; Roche Diagnostics) or rRNA (Pace 2 System; Gen-Probe
Corporation). The Hybrid Capture 2 (HC2) C. trachomatis
detection method is a non-PCR nucleic acid hybridization as-
say that is based on detection of the omp1 gene, as well as the
cryptic plasmid. While these commercial assays are highly ef-
fective for detection of C. trachomatis infection, they do not
permit identification of the different serovars.
Nonetheless, the different serovars of C. trachomatis display
diverse clinical manifestations that merit consideration. When
identification of specific C. trachomatis serovars is desired, they
can be identified on the basis of nucleotide sequence differ-
ences in the ompA gene, which encodes the major outer mem-
brane protein. Phylogenetic analysis of ompA divides strains
into three major serogroups and many serovars, including se-
rogroup B (comprising serovars B/Ba, D/Da, E, L1, and L2/
L2a), serogroup C (comprising serovars A, C, H, I/Ia, J, K, and
L3), and intermediate serogroup I (comprising serovars F
and G/Ga) (3, 30, 33).
Serovars A and B, certain serovar Ba strains, and serovar C
are commonly associated with the ocular disease trachoma
(17). While serovars B and C are rarely found in the urogenital
tract (19), serovars Ba (specifically, the genovariant A7), D/Da,
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E, H, I/Ia, J, K, F, and G/Ga are common in the urogenital
tract and can sometimes be detected in the respiratory tracts of
infants because of transmission during delivery (4). Serovars
D/Da and E are the most commonly recovered types. Serovars
L1, L2/L2a, and L3 are associated with a specific and distinct
condition, lymphogranuloma venereum (16).
A large epidemiologic investigation was initiated to investi-
gate C. trachomatis serovar distribution among women in re-
lationship to several characteristics such as cervical inflamma-
tion, parity, and cervical neoplasia in a province of Costa Rica
that has a traditionally high risk of cervical cancer (9). We
considered the novel PCR-based C. trachomatis Detection and
genoTyping (Ct-DT) assay as a promising candidate approach
that combines sensitive detection of C. trachomatis infection by
a multiplex broad-spectrum PCR with microtiter plate hybrid-
ization (DNA enzyme immunoassay [DEIA]) with C. tracho-
matis typing based on reverse hybridization assay (RHA) (25).
Before we applied the assay to the large epidemiologic anal-
yses, the new Ct-DT assay was validated by comparing the
assay to an FDA-approved, commercially available C. tracho-
matis detection assay (HC2; Digene, Gaithersburg, MD). This
report describes the evaluation of the Ct-DT assay and also
reports our findings on C. trachomatis serovar distribution in
the Costa Rican study population.
MATERIALS AND METHODS
Study population and specimen collection. Cervical specimens were collected
from women participating in the enrolment visit of a community-based double-
blind randomized clinical trial investigating the efficacy of an HPV type 16/18
vaccine to prevent cervical intraepithelial neoplasia grade 2 or 3 or cancer.
Women were identified through a door-to-door population census conducted in
the Province of Guanacaste and adjacent Puntarenas in Costa Rica. Eligible
participants were women 18 to 25 years old living in Guanacaste and adjacent
Puntarenas who were in good general health, had no history of chronic condi-
tions that required treatment, were willing to use a birth control method for a
period covering the 6-month vaccination phase, and lived in the study area with
no plans of imminent departure from the study area. Recruitment began in June
2004 and ended in December 2005. A total of 7,466 women, approximately 30%
of the census, fulfilled the inclusion criteria and were enrolled to receive the
candidate vaccine against HPV type 16/18 or hepatitis A vaccine. All study
protocols were reviewed and approved by the National Cancer Institute (NCI)
and Costa Rican Institutional Review Boards.
At enrolment, women provided written informed consent, and prior to ran-
domization, a questionnaire that inquired about demographics, sexual activity,
contraceptive use, reproductive history, cigarette use, and family history of can-
cers was administered.
At enrolment, a pelvic exam was performed on all consenting, sexually expe-
rienced women, during which exfoliated cervical cells were collected with a
Cervex brush (Rovers Medical Devices BV, Oss, The Netherlands). The cells
were placed in 20 ml of liquid cytology medium (PreservCyt; Cytyc Corporation,
Marlborough, MA) and kept at room temperature. At the cytology laboratory,
two 0.5-ml aliquots were drawn and stored in liquid nitrogen. After aliquoting,
liquid-based cytology samples (ThinPrep; Cytyc Corporation) were prepared.
The remaining PreservCyt sample was used to detect C. trachomatis, Neisseria
gonorrhoeae, and HPV by the HC2 assay (Digene Corporation). Women who
tested positive for C. trachomatis and/or N. gonorrhoeae were offered counseling
and treatment with a single 1-g dose of azithromycin for them and their partners
free of charge as part of the trial protocol. Treatment efficacy was confirmed at
the next study visit with additional C. trachomatis and N. gonorrhoeae tests.
C. trachomatis detection and genotyping. As mentioned, the HC2 C. tracho-
matis assay was performed on all available specimens. One of the two 0.5-ml
aliquots was used to test C. trachomatis by the Ct-DT system (Labo Biomedical
Products, Rijswijk, The Netherlands). The Ct-DT assay was performed on all
HC2 C. trachomatis-positive specimens and 8% of the randomly selected HC2 C.
trachomatis-negative samples. To further investigate discrepant HC2 and Ct-DT
results, a second commercially available C. trachomatis assay (COBAS TaqMan;
Roche Diagnostics) was chosen for adjudication. Neither the HC2 nor the
COBAS TaqMan assay provides information on C. trachomatis serovars. COBAS
TaqMan was used to test all (n  33) samples with discrepant assay results,
Ct-DT borderline positive samples (n  7), 10% of the randomly selected
samples that were negative by both HC2 C. trachomatis and Ct-DT (n 39), and
10% of the randomly selected samples that were positive by both the HC2 C.
trachomatis and Ct-DT assays (n  79).
C. trachomatis testing by HC2. Commercially available assays were performed
according to the manufacturers’ instructions.
HC2 (Digene Corporation, Gaithersburg, MD) is an FDA-approved nucleic
acid hybridization assay with signal amplification that combines antibody capture
of target DNA with RNA probe hybrids and chemiluminescence for signal
detection. The number of relative light units measured compared to a positive
standard (RLU/PC) is used to discriminate against positive and negative sam-
ples.
C. trachomatis testing by HC2 was done in a tiered approach. All samples were
first subjected to a combined HC2 C. trachomatis-N. gonorrhoeae DNA test
according to the manufacturer’s instructions. Briefly, the C. trachomatis-N. gon-
orrhoeae test contains a probe cocktail mixture that is complementary to a total
of approximately 39,300 bp (4%) of the C. trachomatis genomic DNA, 7,500 bp
(100%) of the C. trachomatis cryptic plasmid, 9,700 bp (0.5%) of the N. gonor-
rhoeae genomic DNA, and 4,200 bp (100%) of the N. gonorrhoeae cryptic plas-
mid. This is a qualitative test, and a positive result indicates the presence of C.
trachomatis and/or N. gonorrhoeae DNA in the specimen. A negative test indi-
cates the absence of both C. trachomatis and N. gonorrhoeae or the presence of
DNA at levels below the detection limit of the assay.
Subsequently, all samples positive by the combined C. trachomatis-N. gonor-
rhoeae DNA test were further tested by the HC2 C. trachomatis-specific assay,
which uses the same hybrid capture technology to confirm the presence of C.
trachomatis in each sample. As in all HC2 assays, target DNA is hybridized with
a cRNA probe cocktail and the RNA-DNA hybrids are captured onto an anti-
body-coated microplate well. Immobilized hybrids are incubated with alkaline
phosphatase-conjugated antibodies and detected with a chemiluminescent sub-
strate. Specimens with RLU/PC cutoff value ratios of 1 are considered positive
for C. trachomatis DNA. The two HC2 assays were performed in the laboratory
at the University of Costa Rica in San Jose on residual PreservCyt samples.
C. trachomatis detection and genotyping by Ct-DT. The new Ct-DT assay is a
commercially available assay and was performed according to the manufacturer’s
(Laboratory Biomedical Products BV, Rijswijk, The Netherlands) instructions.
The Ct-DT assay comprises an amplification step, followed by a detection step
by a DEIA. All samples positive at the amplification and detection steps were
subsequently genotyped by RHA by using the same PCR product generated for
the detection assay.
DNA isolation method. Total DNA was isolated from 200-l PreservCyt ali-
quots with the MagNA Pure LC instrument (Roche Diagnostics, Almere, The
Netherlands) and the Total DNA isolation kit (Roche Diagnostics). DNA was
eluted in 100 l of water. Each DNA extraction run contained positive and
negative controls to monitor the DNA isolation procedure.
Ct-DT amplification step. The first part of the Ct-DT assay comprises a PCR
amplification step which uses a C. trachomatis multiplex broad-spectrum PCR
primer mixture with multiple forward and reverse primers targeting the omp1
VD2 region and the cryptic plasmid. The C. trachomatis PCR primer set is
designed to amplify all of the known serovars available in GenBank. Briefly, this
multiplex primer set amplifies a fragment of 241 bp from the cryptic plasmid and
a fragment of 160/157 bp from variable region 2 of the omp1 gene (25).
Briefly the PCR mixture consist of 10 l of isolated DNA, 2.5 mM MgCL2, 1
GeneAmp PCR buffer II, 1.5 U AmpliTaq Gold DNA polymerase (Applied
Biosystems, Foster City, CA), 0.2 mM deoxynucleoside triphosphates (Invitro-
gen, Carlsbad, CA), and 15 pmol of each primer (Eurogentec S.A., Seraing,
Belgium) in a total volume of 50 l. The standard PCR program is a 9-min
preheating step at 94°C, followed by 40 cycles of amplification (30 s at 94°C, 45 s
at 55°C, and 45 s at 72°C) and a final 5-min elongation step at 72°C.
Ct-DT detection step. The specific detection of C. trachomatis amplicons is
performed by a DEIA. PCR products were hybridized to a mixture of conserved
probes for the cryptic plasmid, as well as the omp1 gene (25), to permit detection
of all of the genotypes available in GenBank. Reverse primers contain a biotin
label at the 5 end, enabling capture of the reverse strand onto streptavidin-
coated microtiter plates. Captured amplicons are denatured by alkaline treat-
ment, and the captured strand is detected by a defined cocktail of digoxigenin-
labeled probes. After washing, the hybrids are detected by an enzymatic reaction,
resulting in a colored product. The DEIA provides an optical density (OD) value
at 450 nm. Each DEIA run contained separate titrated positive, borderline-
positive, and negative controls and a PCR-positive control containing isolated
DNA from a cell culture of serovar E. Samples yielding OD values equal to or
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higher than the borderline are considered positive. The borderline positive
samples are C. trachomatis-positive samples that contained the lowest amount of
C. trachomatis amplicon detectable with the Ct-DT assay. The OD value of the
borderline range depends on the titrated borderline internal control and differs
for every single run.
Ct-DT genotyping step. The C. trachomatis-genotyping step from the Ct-DT
assay is based on the RHA technology. Biotin-labeled PCR amplicons from
Ct-DT-positive samples at the detection step were subsequently used to differ-
entiate between the C. trachomatis serovars by RHA on a nitrocellulose strip,
which contains probes for the cryptic plasmid, for the three different C. tracho-
matis serogroups (B, C, and I), and for the 19 serovars (A, B/Ba, C, D/Da, E, F,
G/Ga, H, I/Ia, J, K, L1, L2/L2a, and L3). One extra probe is added to detect a
genovariant of serovar J that otherwise remains undetected. Each RHA run
contains a negative and a positive control (serovar E). The Ct-DT genotyping
step was performed according to the manufacturer’s instructions.
C. trachomatis detection by the COBAS TaqMan assay. The COBAS TaqMan
C. trachomatis test (Roche Molecular Systems, Branchburg, NJ) was performed
according to the manufacturer’s instructions in the laboratory for Medical Mi-
crobiology, Radboud University Nijmegen, Nijmegen, The Netherlands, on re-
sidual isolated DNA samples. This test was run on the Roche Diagnostics
COBAS TaqMan 48 Analyzer, an instrument that offers automated real-time
PCR amplification and detection in a closed system. Systematic internal controls
and built-in cross-contamination prevention mechanisms further enhance the
reliability of the results obtained.
Statistical analysis. The primary outcome was C. trachomatis prevalence de-
termined by the HC2 assay compared with the Ct-DT amplification and detec-
tion step (PCR and DEIA).
Agreement between the two assays was determined by unweighted kappa ()
statistics and 95% confidence intervals (CI), which test percent agreement be-
yond that expected by chance alone. Generally, the kappa values are interpreted
as follows: 0.20, poor agreement; 0.21 to 0.40, fair agreement; 0.41 to 0.60,
moderate agreement; 0.61 to 0.80, good agreement; 0.80, excellent agreement.
In order to maximize information on serovars efficiently, all HC2 C. tracho-
matis-positive samples were tested by the novel Ct-DT assay while we chose an
8% random sample of HC2 C. trachomatis-negative samples to test by Ct-DT.
The percentage of HC2 C. trachomatis-negative samples was decided by labora-
tory resources. In testing a random sample of HC2 C. trachomatis-negative
samples, we presumed that most of the HC2-negative specimens would be neg-
ative by Ct-DT as well and that we could validly estimate the characteristics of
the remaining 92% of the HC2 C. trachomatis-negative samples that were not
tested with Ct-DT by reference to the randomly selected 8% subset. Accordingly,
to report population level data, we extrapolated the observed data to the entire
set of HC2 C. trachomatis-negative samples.
In the extrapolated data, the nonparametric test for matched data (McNemar’s
2 test) was used to determine whether the proportion of samples classified as
positive by the HC2 assay and negative by the Ct-DT assay was equal to the
proportion of samples classified as negative by the HC2 assay and positive by the
Ct-DT assay. We report the results based on observed data that were tested by
both assays, and additionally, we report results based on the extrapolated data
adjusting for the sampling fraction.
RESULTS
Pelvic examinations in which exfoliated cervical cells were
obtained were performed on 5,871 sexually experienced
women enrolled in the trial. HC2 testing was performed for
5,828 specimens; 42 samples were excluded because of an
insufficient specimen volume. The median age of the women
was 21 years (interquartile range, 19 to 23 years), and the
median age at first sexual intercourse was 17 years (interquar-
tile range, 15 to 18 years). Forty-four percent (n  2,564) of
the women were single, 52% (n  3,059) were married, and
3.4% (n  199) reported being separated, divorced, or wid-
owed. Only 16% of the women reported ever having smoked,
and 42% of the women reported only one lifetime sexual
partner.
C. trachomatis detection. C. trachomatis prevalence in the
cohort, as measured by the HC2 assay, was 14% (827/5,828;
95% CI, 13.3 to 15.1). All 827 HC2 C. trachomatis-positive
samples and an additional 402 randomly selected, HC2 C.
trachomatis-negative samples were further analyzed by the
Ct-DT system. Data for the 1,229 paired observations are
shown in Table 1. Of the 1,229 observations, the Ct-DT assay
detected 806 as C. trachomatis positive and 423 as C. tracho-
matis negative.
In the paired data without extrapolation (n  1,229), the
crude agreement between the two assays for C. trachomatis
detection was 97% and the kappa was 0.94 (95% CI, 0.92 to
0.96). It would not be proper to calculate the population-wide
percentage of C. trachomatis-positive specimens, or the relative
positivity of the two assays with McNemar’s test, on the basis of
the data in Table 1 because only a small percentage of the HC2
C. trachomatis-negative samples were tested. Hence, we ex-
trapolated the observed HC2 C. trachomatis-negative samples
to the entire study population. By maintaining the fraction of
samples positive by Ct-DT, we could confidently estimate that
if all of the specimens had been tested, the crude agreement
between the assays would be 98% and the kappa would de-
crease slightly to 0.92 (95% CI, 0.89 to 0.97). The 27 (0.5%)
samples that were HC2 C. trachomatis positive but negative by
the Ct-DT assay were not changed when we reconstituted the
whole Costa Rican study population, but these 27 would be
properly compared to an extrapolated estimate of 75 (1.5%)
samples that would be C. trachomatis positive by Ct-DT assay
but HC2 C. trachomatis negative (McNemar’s P  0.03).
We also examined the agreement between the HC2 and
Ct-DT assays, stratified by age, lifetime number of sexual part-
ners, and marital status. Kappa values remained stable across
age, number of sexual partners, and marital status (data not
shown).
Discrepant analysis by the Roche COBAS TaqMan C. tra-
chomatis test. One hundred fifty-eight samples were further
tested by the commercially available C. trachomatis assay
(COBAS TaqMan) to understand discrepant assay findings,
which included 33 observed discordant samples, 7 border-
line positive by Ct-DT, 79 randomly selected HC2 and
Ct-DT assay-positive samples, and 39 randomly selected
HC2 and Ct-DT-negative samples. Table 2 shows the results
of this analysis. All 79 samples positive by both the HC2 and
Ct-DT assays were also positive by COBAS TaqMan, while
TABLE 1. Agreement between HC2 and Ct-DT assaysa
Ct-DT assay result (no. 	%

of samples)
No. of samples with
observed HC2 assay
results of:
No. of samples with
extrapolated HC2
assay results of:
Negative
(n  402)
Positive
(n  827)
Negative
(n  4,998
	85.8%
)
Positive
(n  827
	14.2%
)
Observed data (1,229)
Negative (423) 396 27
Positive (806) 6 800
Extrapolated data (5,825)
Negative (4,950 	85.0
) 4,923 27
Positive (875 	15.0
) 75 800
a The agreement between observed assay results was 97% (unweighted
kappa  0.94 	CI, 0.92 to 0.96
). The agreement between extrapolated assay
results was 98% (unweighted kappa  0.92 	CI, 0.89 to 0.97
). McNemar’s
P  0.03.
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only 1 of the 39 samples negative by both the HC2 and Ct-DT
assays was positive by COBAS TaqMan. Among the 27 HC2 C.
trachomatis-positive, Ct-DT-negative samples, 25 were nega-
tive by COBAS TaqMan. All five HC2 C. trachomatis-negative,
Ct-DT-positive samples were positive by COBAS (Table 2).
There were eight Ct-DT borderline-positive samples; six were
confirmed as positive by COBAS TaqMan and seven were
confirmed as positive by the HC2 assay. Thus, among the 33
specimens where the HC2 and Ct-DT assays disagreed, COBAS
TaqMan was significantly more likely to agree with the Ct-DT
assay (31/33, P  0.001) than with the HC2 assay.
C. trachomatis serogroups and serovars. Results of serovar
distribution among the 806 women positive by Ct-DT are pre-
sented in Table 3. There were 12 specimens that were positive
for the C. trachomatis plasmid but negative by the genotyping
assay for the 14 serovars that were tested. Among the 806
infections that were Ct-DT plasmid positive, serovar E was the
most common (31%), followed by serovars F and D (both
21%) and serovar I (15%). Sequence analysis of the 10 serovar
B/Ba samples revealed that all belonged to the Ba serotype. As
expected, serovars A, C, L1, L2/L2a, and L3 were not identified
in these samples from the genital tract. The HC2 probe iden-
tified 97 to 100% of all of the C. trachomatis serovars as
positive. There were 14 samples in which multiple C. tracho-
matis serovars were identified, without any evident pattern
(Table 3).
DISCUSSION
We compared the performance of the novel Ct-DT assay
with that of the FDA-approved commercially available HC2 C.
trachomatis assay and found excellent agreement between the
two assays for detection of C. trachomatis.
A particular strength of this interassay comparison is that it
was performed on a large, community-based sample of women.
The study population was large and representative of young
women participating in a clinical trial evaluating an HPV type
16 and 18 prophylactic vaccine. The women were initially
screened for C. trachomatis infection with the HC2 C. tracho-
matis-N. gonorrhoeae assay. When a sample was positive, the
presence of C. trachomatis specifically was determined by an
additional HC2 test for C. trachomatis only. Subsequently, all
HC2 C. trachomatis-positive samples, as well as 8% of the
randomly selected HC2 C. trachomatis-negative samples, were
analyzed with the novel Ct-DT assay. Both assays were per-
formed on samples derived from one specimen from the same
participant, collected in the same medium, thus reducing the
chance that differences could be attributed to procedural vari-
ations. We presented observed and extrapolated agreement
adjusting for the sampling fraction.
In 94% (31/33) of the discordant HC2 and Ct-DT assay results,
the findings of the Ct-DT assay were corroborated by the Roche
COBAS TaqMan assay, which is based on amplification of the
cryptic plasmid and has a sensitivity of approximately 20 copies
per PCR. In particular, all five Ct-DT-positive, HC2-negative
results were also positive by the Roche COBAS TaqMan assay,
suggesting that they were true positive results missed by the
HC2 assay.
The majority of the discordant results were HC2 C. tracho-
matis positive and Ct-DT negative. When we used the HC2
RLU value as a proxy for the burden of infection, we observed
that 25 of these 27 specimens yielded lower bacterial DNA
quantities (values in the lowest RLU quartile between 1 and
27) than those positive by both assays (data not shown). HC2-
positive, Ct-DT-negative findings may be explained either by
sampling error related to a low C. trachomatis load, by false
negativity of the Ct-DT assay, or by false positivity of the HC2
assay. False positivity of the HC2 assay could theoretically be
explained by a lack of specificity and cross-hybridization of the
very long RNA probes used in the HC2 assay with DNA from
TABLE 2. COBAS TaqMan C. trachomatis assay findings for
adjudication of discrepant HC2 and Ct-DT assay results
HC2 result Ct DT result
No. of
samples
testeda
No. of samples with
Roche COBAS
result of:
Negative Positive
Negative Negative 39 38 1
Positive Positive 79 0 79
Negative Positive 5 0 5
Negative Borderline positive 1 1 0
Positive Borderline positive 7 1 6
Positive Negative 27 25 2
a The total number of samples was 158.
TABLE 3. Ct-DT genotyping (serogroup and serovar) assay and
HC2 test results for 806 C. trachomatis-positive samples
Test group and
serogroup(s)
No. of
samples
tested
Serovar(s) No. (%) ofsamples
% HC2
positive
Single infection
B 417 E 245 (30.4) 100.0
D/Da 162 (20.1) 100.0
B/Ba 10 (1.2) 100.0
C 191 I/Ia 121 (15.0) 100.0
J 30 (3.7) 96.7
H 28 (3.5) 100.0
K 12 (1.5) 100.0
I 172 F 165 (20.5) 98.8
G/Ga 7 (0.8) 100.0
Multiple infections
B 1 D/Da  E 1 (0.1) 100.0
B  C 6 D/Da  H 2 (0.2) 100.0
D/Da  I/Ia 1 (0.1) 100.0
D/Da  J 2 (0.2) 100.0
E  I/Ia 1 (0.1) 100.0
B  I 3 D/Da  F 1 (0.1) 100.0
E  F 2 (0.2) 100.0
I 1 F  G 1 (0.1) 100.0
I  C 3 F  I/Ia 1 (0.1) 100.0
F  J 1 (0.1) 100.0
F  K 1 (0.1) 100.0
Plasmid only 12 (1.5) 75.0
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other microorganisms present in the specimen. In the HC2 C.
trachomatis test, 4% of the genome (containing stretches of
conserved and repeat sequences) is covered by a range of RNA
probes which might lead to false positive reactivity.
In addition to detecting the C. trachomatis plasmid, the
Ct-DT assay has been designed to determine the C. trachoma-
tis serogroup and serovar. Although the prevalence of C. tra-
chomatis serovars described in the literature shows consider-
able variation, our results are similar to those of other studies
in Australia (32), Alabama, (8), Sweden (13), Taiwan (11),
China (7), and Korea (15). As in those populations, serovar E
also was the most prevalent type in the present study cohort. In
contrast, in Uganda (25), Thailand (1), and Colombia (20),
serovar E was far less prevalent. This variation may be due to
the use of different methods of C. trachomatis serovar identi-
fication (1) or to the use of a small isolated study population in
Uganda (20, 25). However, there is laboratory evidence sug-
gesting that serovar E can outcompete other strains for nutri-
ents and growth factors, which would suggest a reason for a
rapid expansion of serovar E if, in fact, an expansion can be
inferred from cross-sectional data (12). To address such hy-
potheses, we are currently testing 1,000 age-stratified speci-
mens collected more than 10 years ago in the same region of
Costa Rica from women more than 18 years old.
In the present study, 10 of the 806 Ct-DT-positive samples
tested contained serovar B/Ba. The Ct-DT genotyping test
cannot discriminate between these two strains. Serotype B
strains have only once been found in urogenital samples (B/
Alpha-95) (19). The occurrence of serovar B in urogenital
samples, although observed, is a very rare event. However, the
Ba serotypes have regularly been found at both urogenital and
ocular sites (19). Further sequence analysis of the amplicons
from the 10 samples in this study revealed the presence of
serovar Ba in all cases.
Among the 806 Ct-DT-positive samples that were further
analyzed with the Ct-DT genotyping assay, 12 showed only
positivity for the cryptic plasmid, with no serogroups or sero-
vars identified. The absence of amplification might be due to
either sequence variation in the primer target region of the
omp1 gene or inhibition of omp1 PCR amplification. An alter-
native explanation for the absence of omp1 amplification might
be related to the occurrence of sampling variation. This may
play an important role when samples contain very low numbers
of target molecules or when heterogeneous clinical materials,
such as cervical swabs or biopsy specimens, are used. Every C.
trachomatis bacterium contains 10 to 20 copies of the cryptic
plasmid but only one single omp1 gene. If the isolated DNA
contains only a very low concentration of bacterial DNA, it is
possible that only cryptic-plasmid DNA but no genomic DNA
would be included in the PCR mixture and that only the plas-
mid PCR yields positive results. Similar findings of a positive
plasmid-directed PCR and a negative omp1 PCR have been
reported for genital and conjunctival samples (22, 28).
Both the Ct-DT and HC2 C. trachomatis assays detect the
cryptic plasmid, as well as genomic sequences of C. trachoma-
tis, in a combined assay. In our study, analysis with the Ct-DT
genotyping assay revealed positivity for the cryptic plasmid in
all C. trachomatis-positive samples; however, we could not con-
firm the existence of plasmid-negative strains as previously
reported (5, 24, 29).
In conclusion, we observed excellent agreement between the
HC2 and Ct-DT systems for detection of C. trachomatis. In
addition, the Ct-DT assay permits easy and rapid identification
of the serotype in the positive samples, with the same am-
plimers as used for detection of C. trachomatis positivity. The
present study shows that the Ct-DT assay is a robust method
which can be used for studying the natural history of C. tra-
chomatis and C. trachomatis serovars. We will now use this
assay to perform large-scale epidemiologic investigations re-
garding C. trachomatis serovars and inflammation, parity, and
risk of cervical cancer among HPV-infected women.
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